Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Apolipoprotein M and its impact on endothelial dysfunction and inflammation in the cardiovascular system

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Associations between body mass index trajectories in childhood and cardiovascular risk factors in adulthood

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Omega-3 fatty acids and risk of cardiovascular disease in Inuit: First prospective cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. AHRR hypomethylation as an epigenetic marker of smoking history predicts risk of myocardial infarction in former smokers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Apolipoprotein M and Sphingosine-1-Phosphate Receptor 1 promote the transendothelial transport of High-Density Lipoprotein

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Increased plasma apoM levels impair triglyceride turnover in mice

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Oral pre‑treatment with thiocyanate (SCN−) protects against myocardial ischaemia–reperfusion injury in rats

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Apolipoprotein M - a marker or an active player in type II diabetes?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

Apolipoprotein M (apoM) is a member of the lipocalin superfamily and is predominantly associated with high-density lipoprotein (HDL). It was found that apoM is the chaperon to the bioactive sphingolipid, sphingosine-1-phosphate (S1P). Several studies have since contributed to expand the knowledge on apoM, S1P, and the apoM/S1P-complex in cardiovascular diseases. For instance, the HDL-bound apoM/S1P complex serves as a bridge between HDL and endothelial cells, maintaining a healthy endothelial barrier. Evidence indicates, however, that the apoM/S1P complex may has both protective and harmful effects on the cardiovascular system, which suggests the need for more research to understand the interplay between these molecules. This review aims to shed light on the most recent findings on apoM/S1P-signaling and its impact on endothelial dysfunction, inflammation, and cardiovascular diseases. Finally, it will be discussed whether drugs that target apoM and/or S1P-signaling may be beneficial to patients with cardiovascular and inflammatory diseases.

OriginalsprogEngelsk
TidsskriftAtherosclerosis
Vol/bind334
Sider (fra-til)76-84
Antal sider9
ISSN0021-9150
DOI
StatusUdgivet - okt. 2021

ID: 67567835